Anticoagulant therapy for the prevention and treatment of venous thromboembolism

Iavelov I.S.

doi:https://doi.org/

Iavelov I.S.

Kafedra klinicheskoĭ kardiologii Rossiĭskogo gosudarstvennogo meditsinskogo universiteta im. N.I. Pirogova, Moskva

Anticoagulant therapy for the prevention and treatment of venous thromboembolism

Authors:

Iavelov I.S.

More about the authors

Journal: Journal of Venous Disorders. 2010;4(4): 4‑14

Read: 26587 times

Download PDF (RU)

Contact the author

Table of contents

To cite this article:

Iavelov IS. Anticoagulant therapy for the prevention and treatment of venous thromboembolism. Journal of Venous Disorders. 2010;4(4):4‑14. (In Russ.)

Подписка 2026 Флебология (Journal of Venous Disorders)

Использование инфографики авторами научных работ

References:

Geerts W.H., Bergqvist D., Pineo G.F. et al. Prevention of Venous Thromboembolism. American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition). Chest 2008;133:381-453.
Kearon C., Kahn S.R., Agnelli G. et al. Antithrombotic Therapy for Venous Thromboembolic Disease. American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition). Chest 2008;133:454-545.
Guidelines o the diagnosis and management of acute pulmonary embolism. The Task Force for the Diagnosis and Management of Acute Pulmonary Embolism of the European Society of Cardiology. Eur Heart J 2008;29:2276-2315.
Rossiiskie klinicheskie rekomendatsii po diagnostike, lecheniyu i profilaktike venoznykh tromboembolicheskikh oslozhnenii. Flebologiya 2010;1:2:3-37.
Hirsh J., Bauer K.A., Donati M.B. et al. Parenteral Anticoagulants. American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition). Chest 2008;133:141-159.
Ansell J., Hirsh J., Hylek E. et al. Pharmacology and Management of the Vitamin K Antagonists. American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition). Chest 2008;133:160-198.
Yavelov I.S. Nizkomolekulyarnye gepariny: osnovnye svoistva i vozmozhnosti sozdaniya analogov. Klin farmakol i terap 2010;1:56-63.
Douketis J., Cook D., Meade M. et al. for the Canadian Critical Care Trials Group. Prophylaxis Against Deep Vein Thrombosis in Critically Ill Patients With Severe Renal Insufficiency With the Low-Molecular-Weight Heparin Dalteparin. An Assessment of Safety and Pharmacodynamics: The DIRECT Study. Arch Int Med 2008;168:1805-1812.
Lassen M.R., Raskob G.E., Gallus A. et al. for Thromboprophylaxis after Knee Replacement. N Engl J Med 2009;361:594-604.
Lassen M.R., Raskob G.E., Gallus A. et al. and the ADVANCE-2 investigators. Apixaban versus enoxaparin for thromboprophylaxis after knee replacement (ADVANCE-2): a randomized double-blind trial. Lancet 2010;375:807-815.
Eriksson B.I., Borris L.C., Friedman R.J. et al. for the RECORD1 Study Group. Rivaroxaban versus Enoxaparin for Thromboprophylaxis after Hip Arthroplasty. N Engl J Med 2008;358:2765-2775.
Kakkar A.K., Brenner B., Dahl O.E. et al. for the RECORD2 Investigators. Extended duration rivaroxaban versus short-term enoxaparin for the prevention of venous thromboembolism after total hip arthroplasty: a double-blind, randomized controlled trial. Lancet 2008;372:31-39.
Lassen M.R., Ageno W., Borris L.C. for the RECORD3 Investigators. Rivaroxaban versus Enoxaparin for Thromboprophylaxis after Total Knee Arthroplasty. N Engl J Med 2008;358:2776-2786.
Turpie A.G.G., Lassen M.R., Davidson B.L. et al. for the RECORD4 Investigators. Rivaroxaban versus enoxaparin for thromboprophylaxis after total knee arthroplasty (RECORD4): a randomised trial. Lancet 2009;373:1673-1680.
Eikelboom J.W., Weitz J. Selective factor Xa inhibition for thromboprophylaxis. Lancet 2008;DOI:10.1016/S0140-6736(08)60879-X.
Eriksson B.I., Dahl O.E., Rosencher N. et al. for the RE-MODEL Study Group. Oral dabigatran etexilate vs. subcutaneous enoxaparin for the prevention of venous thromboembolism after total knee replacement: the RE-MODEL randomized trial. J Thromb Haemost 2007;5:2178-2185.
Eriksson B.I., Dahl O.E., Rosencher N. et al. for the RE-NOVATE Study Group. Dabigatran etexilate versus enoxaparin for prevention of venous thromboembolism after total hip replacement: a randomised, double-blind, non-inferiority trial. Lancet 2007;370:949-956.
The RE-MOBILIZE Writing Committee. Oral Thrombin Inhibitor Dabigatran Etexilate vs North American Enoxaparin Regimen for Prevention of Venous Thromboembolism After Knee Arthroplasty Surgery. J Arthroplasty 2009;24:doi:10.1016/j.arth.2008.01.132
Schulman S., Kearon C., Kakkar A.K. et al. for the RE-COVER Study Group. Dabigatran versus Warfarin in the Treatment of Acute Venous Thromboembolism. N Engl J Med 2009;361:2342-2352.
Lee A.Y.Y., Levine M.N., Baker R.I. et al. for the Randomized Comparison of Low-Molecular-Weight Heparin versus Oral Anticoagulant Therapy for the Prevention of Recurrent Venous Thromboembolism in Patients with Cancer (CLOT) Investigators. Low-Molecular-Weight Heparin versus a Coumarin for the Prevention of Recurrent Venous Thromboembolism in Patients with Cancer. N Engl J Med 2003;349:146-153.
Meyer G., Marjanovic Z., Valcke J. et al. Comparison of Low-Molecular-Weight Heparin and Warfarin for the Secondary Prevention of Venous Thromboembolism in Patients With Cancer. A Randomized Controlled Study. Arch Int Med 2002;162:1729-1735.